PMID

Data

Article Title

Organization

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

Pfizer

Ion channels as therapeutic targets: a drug discovery perspective.

Pfizer

Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

Vanderbilt University Medical Center

Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.

Vanderbilt University Medical Center

General Pharmacological Activation Mechanism of K

East China Normal University

Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.

University of Michigan

Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.

University Federico Ii of Naples

Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity.

Chinese Academy of Sciences

Novel K

Glaxosmithkline